Back

Asundexian edges out milvexian: superior stroke reduction with safer bleeding profile in factor XIa inhibition – a network meta-analysis revolutionizing secondary prevention

29 August 2026 (09:50 - 10:00)
Organised by: Logo
Congress Presentation Part of: Optimising antithrombotic therapy in atrial fibrillation Oral Anticoagulation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Krish Sumir Keswani

Vadodara (India)

5 More presentations in this session

Presentation thumbnail
Reduced-dose direct oral anticoagulation vs antiplatelet strategies after left atrial appendage occlusion in atrial fibrillation. a triple target trial emulation from a federated research network
Professor L. Fauchier (Tours, FR)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants in very elderly (≥90 years) patients with atrial fibrillation: observed versus predicted thromboembolism and bleeding risk, and HAS-BLED performance
Doctor K. Abd El Hay (Kfar Saba, IL)
Abstract Slides Video
Presentation thumbnail
Effect of abelacimab vs. rivaroxaban on total bleeding events in patients with atrial fibrillation: an analysis from AZALEA–TIMI 71
Doctor S. Patel (Boston, US)
Abstract Slides Video
Presentation thumbnail
Real-world complication profiles of left atrial appendage occlusion devices: a MAUDE database analysis of 8,406 adverse events
Doctor K. Abdelsayed (Minneapolis, US)
Abstract Slides Video
Presentation thumbnail
Real-world outcomes in women with atrial fibrillation reclassified from anticoagulation-recommended to grey zone by the 2024 ESC CHA₂DS₂-VA score: a global federated network study
Doctor S. Biswas (Meerut, IN)

Access the full session

Session thumbnail
Optimising antithrombotic therapy in atrial fibrillation
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 09:50 CET
You may be interested in
thumbnail
Congress Session
HOT LINE SESSION 5
28 August 2022
thumbnail
Congress Presentation
Safety and efficacy of factor XI/XIa inhibitors compared to factor Xa inhibitors for stroke prophylaxis in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials
30 August 2025
thumbnail
Congress Presentation
Discussant review - OCEANIC-AF
1 September 2024
thumbnail
Congress Presentation
Incidence and predictors of major bleeding among patients receiving apixaban or aspirin for subclinical atrial fibrillation: insights from the ARTESiA sub-analysis
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources